Realizing a World Where People's "Normal Health" is Not Threatened!

Our company supports April Dream, which aims to make April 1st a day to share dreams. This press release is a dream of "AOI Biosciences".

AOI Biosciences Co., Ltd. (Headquarters: Ibaraki City, Osaka Prefecture, Representative Director: Shinichi Sueda) aims to realize a world where people's "normal health" is not threatened, by developing diagnostic, drug discovery, and drug discovery support businesses, primarily in the autoimmune disease and infectious disease fields, through two unique and highly innovative platform technologies: "Neo-self-based technology" and "Allosteric site prediction technology".

**■ Why we are committed to "normal health"**
Being healthy should never be a special thing.
However, in reality, there are people who are suddenly told, "You have an autoimmune disease." There are people who are repeatedly told, "It was another miscarriage, and the cause is unknown." There are people whose lives are threatened by sudden infectious diseases. There are people who have been facing illness for many years with an unknown cause.

In current medical care, about half of the causes of recurrent miscarriage are said to be "unknown." Even for autoimmune diseases, treatment options that fundamentally cure them are still limited. "Unknown," "untreatable"—in the face of these barriers, countless patients around the world continue to suffer.

Since its establishment in 2019, AOI Biosciences has been working to break down these invisible barriers with cutting-edge bioscience, developing its business on three pillars: diagnostics, drug discovery, and drug discovery support. To bring together complex bioscience knowledge and continue to challenge the barriers of "diseases that have not yet been solved," we are advancing the following initiatives:

* **Promotion of "β2GPI Neo-self Antibody Test" (*1), which is attracting attention as a new cause of recurrent miscarriage and infertility.**
* **"Allosteric Drug Discovery" (*2) utilizing quantum-inspired technology with Toshiba Corporation.**
* **Development of a "Next-generation ADC Therapeutic Platform" (*3) aimed at reducing side effects.**

*1 The β2GPI Neo-self Antibody Test is a test that examines new autoantibodies in the blood involved in unexplained infertility, recurrent implantation failure, and unexplained miscarriage.
*2 Allosteric-based Drug Design (ABDD) is a next-generation drug discovery technology that enables drug discovery by detecting new target regions even for proteins that are considered difficult to drug (undruggable targets).
*3 Next-generation ADC (Antibody-Drug Conjugate) is a core technology of precision medicine that has high specificity only for specific affected organs (targeted attack) and minimizes side effects.

And now, we are moving forward to the next stage.

**■ Towards a society where everyone can pursue health without giving up**
"A world where people's 'normal health' is not threatened"
This is AOI Biosciences' company vision and our dream.
Unknown cause. Undiagnosed. No treatment options.
Our mission is to remove these barriers, one by one, where current medical care says "this is the limit," by bringing together the power of diagnostics, information analysis, and drug discovery.

* **For those suffering from infertility and recurrent miscarriage, a day when they can know the cause and hold their baby.**
* **Towards a future where those facing autoimmune diseases can receive fundamental treatment.**
* **Towards a future where life is not suddenly threatened by infectious diseases.**
* **Towards a world where new options can be delivered to those with intractable diseases who were told "there is no treatment."**

This dream is not an idealism of a small bio-venture. We are seriously committed to business growth to deliver our solutions to more patients, more widely, and more quickly. We believe it is also our responsibility to continue to return knowledge from complex research areas to society in a sustainable manner.

Nurturing research dreams with the power of society.
AOI Biosciences will continue to challenge with pride and positivity.

**■ About AOI Biosciences**
Company Name: AOI Biosciences Co., Ltd. (https://www.aoibio.com)
Business Overview: Primarily in the infectious disease and autoimmune disease fields, we develop diagnostic, drug discovery, and drug discovery support businesses by integrating information analysis technology and proprietary bio-technology.
Company Establishment: November 2019

**■ Contact for this news release**
e-mail: information@aoibio.com